1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Diarrhea - Pipeline Review, H1 2017

Diarrhea - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 163 pages

Diarrhea - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea – Pipeline Review, H1 2017, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 15, 2, 21 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Diarrhea - Pipeline Review, H1 2017
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diarrhea - Overview 8
Diarrhea - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Diarrhea - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Diarrhea - Companies Involved in Therapeutics Development 28
A. Menarini Industrie Farmaceutiche Riunite Srl 28
Actelion Ltd 28
Aegis Therapeutics LLC 29
Akthelia Pharmaceuticals Ltd 29
Albireo Pharma Inc 30
AmpliPhi Biosciences Corp 31
Anatara Lifesciences Limited 32
Ardelyx Inc 32
Assembly Biosciences Inc 33
AzurRx BioPharma Inc 33
Bharat Biotech International Ltd 34
CinRx Pharma LLC 34
Codagenix Inc 35
Cosmo Pharmaceuticals NV 35
DesignMedix Inc 36
DiscoveryBiomed Inc 36
Genextra Spa 37
GlaxoSmithKline Plc 37
GP Pharm SA 38
Miyarisan Pharmaceutical Company Ltd 38
Mucosis BV 39
Napo Pharmaceuticals Inc 39
Nippon Shinyaku Co Ltd 40
Novartis AG 40
Pfizer Inc 41
Prokarium Ltd 41
Rebiotix Inc 42
Recce Ltd 42
RedHill Biopharma Ltd 43
RxBio Inc 43
Scandinavian Biopharma Holding AB 44
Sigmoid Pharma Ltd 44
Summit Therapeutics Plc 45
Synthetic Biologics Inc 45
Syntiron LLC 46
Tasly Pharmaceutical Group Co Ltd 46
Wuhan Institute of Biological Products Co Ltd 47
Diarrhea - Drug Profiles 48
ABCD-01 - Drug Profile 48
ABIM-101 - Drug Profile 50
AKT-10081 - Drug Profile 51
ASP-7147 - Drug Profile 52
AZX-1101 - Drug Profile 53
Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 54
cadazolid - Drug Profile 55
Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile 57
CBM-588 - Drug Profile 59
cholestyramine - Drug Profile 61
crofelemer DR - Drug Profile 62
Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 66
elsiglutide - Drug Profile 67
Escherichia coli vaccine - Drug Profile 69
ETEC vaccine - Drug Profile 70
ETEC vaccine - Drug Profile 71
Etvax - Drug Profile 72
GVXNSD-133 - Drug Profile 74
GXG-8 - Drug Profile 76
ibodutant - Drug Profile 77
IMSUTMR-1501 - Drug Profile 78
infectious diarrhea [serotype H11] vaccine - Drug Profile 79
LJN-452 - Drug Profile 80
obeticholic acid - Drug Profile 81
octreotide acetate - Drug Profile 92
octreotide acetate MAR - Drug Profile 93
ondansetron hydrochloride CR - Drug Profile 94
ORP-101 - Drug Profile 100
Peptide to Activate NHE-3 for Diarrhea - Drug Profile 101
PF-06425090 - Drug Profile 102
prulifloxacin - Drug Profile 104
PZ-7475 - Drug Profile 106
RBX-2660 - Drug Profile 107
RDX-98940 - Drug Profile 110
RECCE-355 - Drug Profile 111
Recombinant Enzyme for Diarrhea - Drug Profile 112
ribaxamase - Drug Profile 113
ridinilazole - Drug Profile 119
rifamycin CR - Drug Profile 125
Rotavac-5C - Drug Profile 128
rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile 129
Rx-100 - Drug Profile 130
Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 132
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 133
Small Molecules for Microbial Infections - Drug Profile 134
Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile 135
Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 136
SYN-006 - Drug Profile 137
SYN-007 - Drug Profile 138
Typhetec - Drug Profile 139
Vaccine 1 for Diarrhea - Drug Profile 140
Vaccine 2 for Diarrhea - Drug Profile 141
Vaccine for Traveler's Diarrhea - Drug Profile 142
Vaccine for Traveler's Diarrhea - Drug Profile 143
Yersinia pestis vaccine - Drug Profile 144
Diarrhea - Dormant Projects 145
Diarrhea - Discontinued Products 147
Diarrhea - Product Development Milestones 148
Featured News and Press Releases 148
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 158
Disclaimer 159

List of Tables
Number of Products under Development for Diarrhea, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
Diarrhea - Pipeline by Actelion Ltd, H1 2017
Diarrhea - Pipeline by Aegis Therapeutics LLC, H1 2017
Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017
Diarrhea - Pipeline by Albireo Pharma Inc, H1 2017
Diarrhea - Pipeline by AmpliPhi Biosciences Corp, H1 2017
Diarrhea - Pipeline by Anatara Lifesciences Limited, H1 2017
Diarrhea - Pipeline by Ardelyx Inc, H1 2017
Diarrhea - Pipeline by Assembly Biosciences Inc, H1 2017
Diarrhea - Pipeline by AzurRx BioPharma Inc, H1 2017
Diarrhea - Pipeline by Bharat Biotech International Ltd, H1 2017
Diarrhea - Pipeline by CinRx Pharma LLC, H1 2017
Diarrhea - Pipeline by Codagenix Inc, H1 2017
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
Diarrhea - Pipeline by DesignMedix Inc, H1 2017
Diarrhea - Pipeline by DiscoveryBiomed Inc, H1 2017
Diarrhea - Pipeline by Genextra Spa, H1 2017
Diarrhea - Pipeline by GlaxoSmithKline Plc, H1 2017
Diarrhea - Pipeline by GP Pharm SA, H1 2017
Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
Diarrhea - Pipeline by Mucosis BV, H1 2017
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H1 2017
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
Diarrhea - Pipeline by Novartis AG, H1 2017
Diarrhea - Pipeline by Pfizer Inc, H1 2017
Diarrhea - Pipeline by Prokarium Ltd, H1 2017
Diarrhea - Pipeline by Rebiotix Inc, H1 2017
Diarrhea - Pipeline by Recce Ltd, H1 2017
Diarrhea - Pipeline by RedHill Biopharma Ltd, H1 2017
Diarrhea - Pipeline by RxBio Inc, H1 2017
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2017
Diarrhea - Pipeline by Sigmoid Pharma Ltd, H1 2017
Diarrhea - Pipeline by Summit Therapeutics Plc, H1 2017
Diarrhea - Pipeline by Synthetic Biologics Inc, H1 2017
Diarrhea - Pipeline by Syntiron LLC, H1 2017
Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H1 2017
Diarrhea - Dormant Projects, H1 2017
Diarrhea - Dormant Projects, H1 2017 (Contd..1), H1 2017
Diarrhea - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Diarrhea, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I) - Pipeline Review, H2 2016

Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative ...

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2016

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.